

Annual General Meeting in Oncology Venture A/S

PROXY/VOTING BY CORRESPONDENCE FORM

for use at the annual general meeting in Oncology Venture A/S on Wednesday 22 April 2020 at 3:00 pm (CET).

Name: _____

Address: _____

(Please use CAPITAL LETTERS)

I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below:

Please check off field A), B), C) or D):

- A) Proxy is granted to a named third party (**deadline Tuesday 21 April 2020 end of day (CET)**):

Name: _____

Address: _____

(Please use CAPITAL LETTERS)

or

- B) Proxy is granted to the board of directors (with a right of substitution) to vote in accordance with the board of directors' proposals as set out in the table below (**deadline Tuesday 21 April 2020 end of day (CET)**).

or

- C) Check-the-box Proxy is granted to the board of directors (with a right of substitution) to vote as stated below. Please check off the boxes "FOR", "AGAINST" or "ABSTAIN" to indicate your vote (**deadline Tuesday 21 April 2020 end of day (CET)**).

or

- D) Written votes (voting by correspondence) are submitted as stated below. Written votes cannot be withdrawn. Please check off the boxes "FOR", "AGAINST" or "ABSTAIN" to indicate your vote (**deadline Tuesday 21 April 2020 end of day (CET)**).

Agenda

The complete agenda is included in the notice to convene the annual general meeting.

If the votes attaching to a shareholder's shares are cast differently in relation to a specific agenda item, this shall be indicated in the table below.

AGENDA ITEMS	FOR	AGAINST	ABSTAIN	RECOMMENDATION FROM THE BOARD
(a) The board of director's report on the company's activities during the past year				
(b) Adoption of the audited annual report 2019	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(c) Application of profit/Covering of loss according to the adopted annual report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(d) Discharge of the board of directors and the management board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(e) Election of members to the board of directors (see below)				
(1) Duncan Moore	<input type="checkbox"/>		<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(2) Frank Knudsen	<input type="checkbox"/>		<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(3) Steve Carchedi	<input type="checkbox"/>		<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(4) Steen Knudsen	<input type="checkbox"/>		<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(5) Gunnar Magnus Persson	<input type="checkbox"/>		<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(6) Carani Sanjeevi	<input type="checkbox"/>		<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(f) Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as auditor				FOR

	<input type="checkbox"/>		<input type="checkbox"/>	
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(g) Any other business				
1. Proposal to authorize the board of directors to issue convertible loan notes and carry out the appurtenant capital increase	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
2. Proposal to authorize the board of directors to increase the share capital	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
3.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
4.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
<i>(Indicate votes if cast differently (no. of shares)):</i>				
(h) Any other business				

The proxy applies to all business being transacted at the annual general meeting. In the event that new proposals are submitted, including amendments or proposals for election of members to the board of directors or auditor, that are not on the agenda, the proxy holder will vote on your behalf according to his/her best belief. Written votes (voting by correspondence) will be taken into account if a new or an amended proposal is substantially the same as the original.

If the form is only dated and signed, it will be considered a proxy to the board of directors to vote in accordance with the recommendations of the board of directors as stated above.

If the form is only partially completed, votes will be cast in accordance with the recommendations of the board of directors as stated above with respect to the non-ticked off boxes.

The proxy/voting by correspondence is valid for the number of shares that the undersigned holds on the record date, 15 April 2020 end of day (CET), as calculated based on (i) the number of shares registered in the company's register of shareholders and (ii) notifications of ownership received by the company but not yet registered in the company's register of shareholders.

Date: _____ 2020

Name:

Title:

Name:

Title:

*The dated and signed form, if used as a proxy (box A-C above) or for written votes (voting by correspondence) (box D above), must reach Oncology Venture A/S no later than **21 April 2020**, either by email to hm@oncologyventure.com or by ordinary mail to the Company's address: Venlighedsvej 1, 2970 Hørsholm, Denmark.*